ATE331796T1 - Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon - Google Patents

Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Info

Publication number
ATE331796T1
ATE331796T1 AT04709218T AT04709218T ATE331796T1 AT E331796 T1 ATE331796 T1 AT E331796T1 AT 04709218 T AT04709218 T AT 04709218T AT 04709218 T AT04709218 T AT 04709218T AT E331796 T1 ATE331796 T1 AT E331796T1
Authority
AT
Austria
Prior art keywords
cea
rhcea
antigen
development
rhesus
Prior art date
Application number
AT04709218T
Other languages
English (en)
Inventor
L Aurisicchio
Gennaro Ciliberto
Armin Lahm
Monica Nicola La
P Monaci
Fabio Palombo
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE331796T1 publication Critical patent/ATE331796T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04709218T 2003-02-13 2004-02-09 Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon ATE331796T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44720303P 2003-02-13 2003-02-13

Publications (1)

Publication Number Publication Date
ATE331796T1 true ATE331796T1 (de) 2006-07-15

Family

ID=32869610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709218T ATE331796T1 (de) 2003-02-13 2004-02-09 Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Country Status (9)

Country Link
US (1) US20060228335A1 (de)
EP (1) EP1597370B1 (de)
JP (1) JP2006518202A (de)
AT (1) ATE331796T1 (de)
AU (1) AU2004211481A1 (de)
CA (1) CA2514969A1 (de)
DE (1) DE602004001395T2 (de)
ES (1) ES2267046T3 (de)
WO (1) WO2004072287A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658370A1 (de) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Für das karzinoembryonale antigen aus rhesusaffe codierendes synthetisches gen und verwendungen davon
ES2387850T3 (es) * 2004-02-11 2012-10-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Proteína de fusión al antígeno carcinoembrionario y sus usos
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274087A (en) * 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
CA2102623C (en) * 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
AU1013601A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1658370A1 (de) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Für das karzinoembryonale antigen aus rhesusaffe codierendes synthetisches gen und verwendungen davon

Also Published As

Publication number Publication date
WO2004072287A1 (en) 2004-08-26
EP1597370B1 (de) 2006-06-28
US20060228335A1 (en) 2006-10-12
CA2514969A1 (en) 2004-08-26
DE602004001395D1 (de) 2006-08-10
ES2267046T3 (es) 2007-03-01
DE602004001395T2 (de) 2007-08-09
JP2006518202A (ja) 2006-08-10
EP1597370A1 (de) 2005-11-23
AU2004211481A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
MX2009003873A (es) Proteina de fusion de transcriptasa inversa de telomerasa, nucleotidos que la codifican y usos de la misma.
EP1716173B8 (de) Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
MX2025004598A (es) Receptores antigenicos quimericos con especificidad para bcma y usos de estos
DE602004027902D1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
WO2004099247A3 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
DE60235041D1 (de) Und ihre verwendung
EP4279086A3 (de) Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
PT1516932E (pt) Poxvírus com especificidade para infecção dirigida para um alvo
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE461939T1 (de) Melanom-assoziierte mhc klasse i assoziierte oligopeptide und deren verwendungen
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
DE602004001395D1 (de) Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon
GB0418388D0 (en) Cell therapy
Park et al. Effective immunotherapy of cancer by DNA vaccination
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
Hatzi et al. B-cell chronic lymphocytic leukemia (B-CLL) cells express antibodies reactive with antigenic epitopes expressed on the surface of common bacteria.
WO2003084996A3 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
WO2004015098A3 (en) Rhesus epithelial cell adhesion molecule, nucleic acid encoding the same, and uses thereof
Gendron et al. Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties